Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725811 | 0.85 | MAPT (0.32) | MAPTHPGDL3MBTL1POLBALDH1A1 | |
| SCHEMBL6897141 | 0.82 | TSHR (0.50) | NPC1KMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL3566684 | 0.79 | ALOX5 (0.44) | RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5174398 | 0.79 | NOS3 (0.50) | NOS3NOS1MAPTRAB9ANPC1 | |
| SCHEMBL5635324 | 0.78 | ALDH1A1 (0.41) | MAPTRAB9ANPC1MAPK1KDM4E | |
| SCHEMBL4053439 | 0.77 | MAPT (0.44) | NOS3NOS1MAPTRAB9ANPC1 | |
| SCHEMBL3615251 | 0.77 | ALDH1A1 (0.41) | NOS3NOS1MAPTRAB9ANPC1 | |
| SCHEMBL3606664 | 0.77 | CA2 (0.40) | MAPTRAB9ANPC1KDM4EHPGD | |
| SCHEMBL3647821 | 0.75 | LMNA (0.57) | NOS3NOS1MAPTRAB9ANPC1 | |
| SCHEMBL320721 | 0.75 | KCNN4 (0.42) | NOS3NOS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288398-B2 | Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones | MERCK SERONO SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20120238575-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20080287474-A1 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones | LABORATOIRES SERONO SA (CH) | 2008-11-20 | — | — | US | disclosed |
| EP-1957469-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | Laboratoires Serono SA (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065940-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | LABORATOIRES SERONO S.A. (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287474-A1 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones | TYMP, DHFR, DPYD | NOS3 1299/4885NOS1 1222/4885MAPT 4664/4885 |
| US-20120238575-A1 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES | TYMP, DHFR, DPYD | NOS3 1299/4885NOS1 1222/4885MAPT 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.